Skip to main content
. 2014 Dec 27;6(2):162–167. doi: 10.1021/ml500459f

Figure 2.

Figure 2

(a) Competition assay characteristic of irreversible LasR inhibition by 28. (b) Antagonist bioassay for 28 and succinimide 29 with (S)-2-(4-bromophenyl)-N-(2-oxotetrahydrofuran-3-yl) acetamide (Br-HSL) as a positive control for antagonism. (c) The structures and biological activity of succinimide containing ligands 29 and 30.